118. Myelomeningocele Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 5 Drugs : 7 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 10

Drugs and their primary sponsors and trial info
Atosiban   
   University of Sao Paulo General Hospital
      2017   -   NCT04468568   Brazil;
Botulinum A toxin   
   University of Aarhus
      2005   Phase 4   NCT00175123   Denmark;
Contrast Enhanced Voiding Urosonography with Urodynamic Testing   
   University of Virginia
      2021   -   NCT04738539   United States;
Endoscopic repair of myelomeningocele before 26 SA   
   Assistance Publique - Hôpitaux de Paris
      2017   -   NCT02390895   France;
Fetal surgery for MMC repair   
   University Children's Hospital, Zurich
      2019   -   NCT04027374   Switzerland;
In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique   
   University of Southern California
      2018   -   NCT04362592   United States;
In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique   
   University of Southern California
      2018   -   NCT04362592   United States;
MMC   
   OSAKA UniversityDepartment of MedicineDivision of Obstetrics and Gynecology
      2019   -   JPRN-UMIN000040088   Japan;
Minimally invasive fetoscopic repair of MMC   
   Mayo Clinic
      2019   -   NCT03936322   United States;
Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)   
   Marmara University
      2016   -   NCT04186338   -
Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix   
   Diana Lee Farmer
      2021   Phase 1/Phase 2   NCT04652908   United States;
Terbutaline   
   University of Sao Paulo General Hospital
      2017   -   NCT04468568   Brazil;